Pemphigus vulgaris is a chronic blistering disease. Clinically it is characterized by painful intra-epidermal bullae and superficial vesicles involving both the skin and mucosal areas. The diagnosis ...

Pemphigus vulgaris is a potentially fatal autoimmune mucocutaneous blistering disease. Conventional therapy consists of high-dose corticosteroids, immunosuppressive agents, and intravenous immune ...

Please provide your email address to receive an email when new articles are posted on . A 37-year-old woman presents with oral lesions consistent with pemphigus vulgaris and is treated with prednisone ...

Significantly more patients with moderate-to-severe pemphigus sustained their complete remission with rituximab (Rituxan) than with mycophenolate mofetil (MMF), a randomized trial showed. At 1 year, ...

Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin. Pemphigus is ...

Pemphigus refers to a group of skin disorders that cause blistering and sores on the skin or mucous membranes of the mouth, nose, throat or genital region. The onset of disease is usually in ...

This is a rare autoimmune skin disorder that occurs when your immune system starts attacking healthy epidermis cells (the top layer of your skin). Pemphigus can manifest itself as blisters and sores ...

Presents the case of a pregnant woman with erosions and desquamation with erythematose areas only on the gingiva due to Pemphigus vulgaris. Gingival lesions comprise severe desquamative or erosive ...

IN the consideration of vesiculating and bullous eruptions of the oral mucosa, insufficient attention has been given to benign mucous-membrane pemphigus as a distinct clinical entity. Also, in many ...

A retrospective review was conducted on patients with the immunopathological diagnosis of pemphigus examined between 1 January 2000 and 1 April 2010. Uncorrected distance visual acuity (UDVA), best ...

(HealthDay)—For patients with pemphigus vulgaris, rituximab is superior to mycophenolate mofetil for producing sustained complete remission at 52 weeks, according to a study published online May 19 in ...